Uganda
Tuberculosis profile
| High TB burden | High HIV burden |
Population  2013 38 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 4.1 (2.2–6.6) 11 (5.8–18)
Mortality (HIV+TB only) 7.2 (5–9.9) 19 (13–26)
Prevalence  (includes HIV+TB) 58 (32–91) 154 (85–243)
Incidence  (includes HIV+TB) 62 (56–73) 166 (149–193)
Incidence (HIV+TB only) 32 (29–38) 86 (77–102)
Case detection, all forms (%) 73 (63–81)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 1.4 (0.6–2.2) 12 (6.8–19)
MDR-TB cases among notified pulmonary
TB cases
540 (230–840) 490 (270–780)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 25 442   1 312
Pulmonary, clinically diagnosed 12 852   615
Extrapulmonary 5 328    
       
Total new and relapse 45 549    
Previously treated, excluding relapses 2 101    
Total cases notified 47 650    
Among 25 408 new cases:
649 (3%) cases aged under 15 years; male:female ratio: 1.9
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 92 (<1%) 397 (10%) 549
Laboratory-confirmed RR-/MDR-TB cases     117
Patients started on MDR-TB treatment     199
TB/HIV 2013 Number (%)
TB patients with known HIV status 43 318 (91)
HIV-positive TB patients 20 648 (48)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 19 902 (96)
HIV-positive TB patients on antiretroviral therapy (ART) 13 399 (65)
HIV-positive people screened for TB 675 373  
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 77
Previously treated cases, excluding relapse, registered in 2012 66
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 77
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 3.5
Culture (per 5 million population) 0.5
Drug susceptibility testing (per 5 million population) 0.5
Sites performing Xpert MTB/RIF 37
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 39
% Funded domestically 5%
% Funded internationally 14%
% Unfunded 81%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-05-26 Data: www.who.int/tb/data